🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Joel Greenblatt’s CYTK Holdings & Trades

First Buy
Q1 2017
Duration Held
4 Quarters
Largest Add
Q1 2017
+49,907 Shares
Current Position
5,367 Shares
$457,215 Value

Joel Greenblatt's CYTK Position Overview

Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 5,367 shares of Cytokinetics, Incorporated (CYTK) worth $457,215, representing 0.00% of the portfolio. First purchased in 2017-Q1, this short-term holding has been held for 4 quarters.

Based on 13F filings, Joel Greenblatt has maintained this position in CYTK for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2026, adding 5,367 shares. Largest reduction occurred in Q2 2017, reducing 33,047 shares.

Analysis based on 13F filings available since 2013 Q2

Joel Greenblatt's Cytokinetics Incorporated (CYTK) Holding Value Over Time

Track share changes against reported price movement

Quarterly Cytokinetics Incorporated (CYTK) Trades by Joel Greenblatt

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +5,367 New Buy 5,367 $85.19
Q3 2017 -16,860 Sold Out 0 $0.00
Q2 2017 -33,047 Reduce 66.22% 16,860 $12.10
Q1 2017 +49,907 New Buy 49,907 $12.84

Joel Greenblatt's Cytokinetics Incorporated Investment FAQs

Joel Greenblatt first purchased Cytokinetics, Incorporated (CYTK) in Q1 2017, acquiring 49,907 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Joel Greenblatt has held Cytokinetics, Incorporated (CYTK) for 4 quarters since Q1 2017.

Joel Greenblatt's largest addition to Cytokinetics, Incorporated (CYTK) was in Q1 2017, adding 49,907 shares worth $641,000.

According to the latest 13F filing for Q2 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 5,367 shares of Cytokinetics, Incorporated (CYTK), valued at approximately $457,215.

As of the Q2 2026 filing, Cytokinetics, Incorporated (CYTK) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.

Joel Greenblatt's peak holding in Cytokinetics, Incorporated (CYTK) was 49,907 shares, as reported at the end of Q1 2017.